Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
inulin · 1 trial · 1 indication
Serum LPS levels will be measured at baseline and at 8 weeks to evaluate the effect of inulin supplementation compared to placebo.
| Arm | Type | Description |
|---|---|---|
| Placebo (Maltodextrin) | PLACEBO_COMPARATOR | Participants receive maltodextrin powder in identical sachets. Dose is escalated over 2 weeks to match the dosing schedule of the inulin arms (5 g daily for 3 days, 10 g daily for 4 days, then 15 g daily). Sachets are mixed with food or beverage and taken once daily with the largest meal, for 8 weeks. |
| Inulin 10 g/day | EXPERIMENTAL | Participants receive inulin powder in identical sachets. Dose is escalated to 10 g daily (5 g daily for 3 days, then 10 g daily for 4 days). After Week 2, participants continue with one 15 g sachet containing a 2:1 blend of inulin and maltodextrin, providing a daily dose of 10 g inulin. Sachets are mixed with food or beverage and taken once daily with the largest meal, for 8 weeks. |
| Inulin 15 g/day | EXPERIMENTAL | Participants receive inulin powder in identical sachets. Dose is escalated to 15 g daily (5 g daily for 3 days, 10 g daily for 4 days, then 15 g daily). Sachets are mixed with food or beverage and taken once daily with the largest meal, for 8 weeks. |
| Name | Type | Description |
|---|---|---|
| inulin | DRUG | Inulin is a fermentable prebiotic fiber derived from chicory root. For this study, inulin is packaged into single-dose sachets containing 5 g, 10 g, or 15 g of powder. Participants in the 10 g arm escalate from 5 g/day for 3 days to 10 g/day, then continue with sachets containing a 2:1 blend of inulin and maltodextrin to provide a daily 10 g inulin dose. Participants in the 15 g arm escalate from 5 g/day for 3 days, 10 g/day for 4 days, then 15 g/day for the remaining 8 weeks. Sachets are mixed with food or beverage and taken once daily with the largest meal. |
| Maltodextrin (Placebo) | DRUG | Maltodextrin is a carbohydrate powder widely used as a food additive. For this study, maltodextrin is used as the placebo comparator. It is packaged into single-dose sachets identical in appearance and taste to inulin sachets. Participants receive escalating doses (5 g/day for 3 days, 10 g/day for 4 days, then 15 g/day) for a total of 8 weeks. Sachets are mixed with food or beverage and taken once daily with the largest meal. |
Inclusion Criteria: * Provision of signed and dated informed consent form. * Stated willingness to comply with all study procedures and availability for the duration of the study (8 weeks). * Male or female, aged ≥ 40 years. * Established patient in the VA Connecticut Healthcare System * At least o...
Inulin is an investigational small molecule being studied for knee osteoarthritis. It is being evaluated in a Phase 2 clinical trial for its potential to reduce inflammation and knee pain in older adults with this condition. The drug is not yet approved and remains in clinical development.
Inulin is being studied for its effects on inflammation in knee osteoarthritis. While the specific molecular target is not disclosed, the ongoing trial focuses on reducing inflammation and knee pain in older adults with the condition. The trial is biomarker-selected, indicating a focus on particular patient characteristics.
Inulin is being developed by National Healthcare Corp. (ticker: NHC). The company is conducting a Phase 2 clinical trial of inulin for knee osteoarthritis in the United States.
Inulin is in Phase 2 clinical development for knee osteoarthritis. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is not yet recruiting participants.
Inulin is being studied in one Phase 2 clinical trial, NCT07189585, titled "Inulin Supplementation for Reducing Inflammation and Knee Pain in Older Adults With Osteoarthritis." This randomized, double-blind, placebo-controlled trial plans to enroll 84 participants aged 40 years and older in the United States.
Inulin is the primary name used for this investigational drug in clinical development. No alternative names have been reported for this asset in the context of knee osteoarthritis research.